Effect of ASTA-Z 7575 (INN Maphosphamide) on Human Lymphokine-Activated Killer Cell Induction

References

• Brock N. Comparative pharmacologic study in vitro and in vivo with cyclophosphamide (NSC-26271), cyclophosphamide metabolites and plain nitrogen mustard compounds. Cancer Treat. Rep. 1976; 60: 301
   PubMedGoogle Scholar
• Connors T. A. Alkylating drugs, nitrosoureas and alkyltriazenes. Cancer Chemotherapy 1982, H. M. Pinedo. The EORTC Cancer Chemotherapy Annual 4, Excerta Medica, Amsterdam, Oxford 1982; 29
   Google Scholar
• Neta R., Winkelstein A., Salvia S. B., Mendelow H. The effect of cyclophosphamide on suppressor cells in guinea pigs. Cell Immunol. 1977; 33: 402
   PubMed Web of Science ®Google Scholar
• Putman C. W., Halgrimson C. G., Growth C. G., Kashiwaje N., Porter K. A., Starjl T. E. Immunosuppression with cyclophosphamide in the dog. Clin. Exp. Immunol. 1975; 22: 323
   Google Scholar
• Winkelstein A. Mechanism of immunosuppression: Effects of cyclophosphamide on cellular immunity. Blood 1973; 41: 273
   PubMed Web of Science ®Google Scholar
• Sjogren H. O., Hellstrom I., Bansal S. C., Warner G. A., Hellstrom K. E. Elution of blocking factors from human tumors capable of abrogating tumor-cell destruction by specially immune lymphocytes. Int. J. Cancer 1972; 9: 274
   PubMed Web of Science ®Google Scholar
• Turk J. L., Polak L., Parker D. Control mechanisms in delayed-type hypersensitivity. Br. Med. Bull. 1976; 32: 165
   PubMedGoogle Scholar
• Lagrange P. H., Mackaness G. B., Miller T. E. Potentiation of T-cell-mediated-immunity by selective suppression of antibody formation with cyclophosphamide. J. Exp. Med. 1974; 139: 1529
   PubMed Web of Science ®Google Scholar
• Askenase P. W., Hayden B., Gershon R. K. Augmentation of delayed type hypersensitivity by doses of cyclophosphamide which do not affect antibody synthesis. J. Exp. Med. 1975; 141: 697
   PubMed Web of Science ®Google Scholar
• Mitsuoka A., Morikawa S., Baba M., Harada T. Cyclophosphamide eliminates suppressor T-cells in age-associated central regulation of delayed hypersensitivity in mice. J. Exp. Med. 1979; 149: 1018
   PubMed Web of Science ®Google Scholar
• Ray P. K., Raychaudhuri S. Low-dose cyclophosphamide inhibition of transplantable fibrosarcoma growth by augmentation of me host immune response. JNCI 1981; 67: 1341
   PubMedGoogle Scholar
• Niemeyer U., Engel J., Scheffler G., Molge K., Sauerbier D., Weigert W. Chemical characterization of ASTA-Z 7575 (INN mafosphamide CIS-4-Sulfoethyl-thiocyclophosphamide), a stable derivative of 4-hydroxy-cyclophosphamide. Invest. New Drugs 1984; 2: 133
   PubMed Web of Science ®Google Scholar
• Hilgard P., Brock N. The key role of hydroxylation for the cytostatic activity and selectivity of cyclophosphamide. Invest. New Drugs 1984; 2: 131
   PubMed Web of Science ®Google Scholar
• Diamantstein T., Willinger E., Reinman J. T-suppressor cells sensitive to cyclophosphamide and to its in vitro active derivative 4-hydroperoxycyclophosphamide control the mitogenic response of murine splenic B-cells to dextran sulfate. A direct proof for different sensitivities of lymphocytes subsets to cyclophosphamide. J. Exp. Med. 1979; 150: 1571
   Google Scholar
• Douay L., Corin N. C., Laporte J. P., Lopez M., Najman A., Duhamel G. ASTA-Z 7575 (INN Mafosphamide) for the in vitro treatment of human leukemic bone marrows. Invest. New Drugs 1984; 2: 187
   PubMed Web of Science ®Google Scholar
• Taniguchi T., Matsui H., Fusita T. Structure and expression of a clonal cDNA for human interleukin-2. Nature (Lond.) 1983; 302: 305
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A. Immunotherapy of cancer using interleukin-2: Current status and future prospects. Immunol. Today 1988; 9: 58
   PubMedGoogle Scholar
• Grimm E. A., Mazumder A., Zhang H. Z., Rosenberg S. A. Lymphokine-activated killer cell phenomenon. Lysis of natural-killer resistant fresh solid tumor cells by interleukin-2-activated lymphocytes. J. Exp. Med. 1982; 155: 1823
   PubMed Web of Science ®Google Scholar
• Anderson T. M., Ibayashi Y., Tokuda Y., Coloquhoun S. D., Holmes E. C., Golub S. H. Effects of systemic recombinant interleukin-2 on natural killer and lymphokine activated killer activity of human tumor infiltrating lymphocytes. Cancer Res. 1988; 48: 1180
   PubMed Web of Science ®Google Scholar
• Lindemann R. A., Singh K. P., Shau H., Gupta R. K. The effects of staphylococcal protein A on human lymphokine-activated killer cell induction. Cancer Immunol. Immunother. 1991; 33: 97
   Google Scholar
• Singh K. P., Shau H., Gupta R. K., Kopald K., Ray P. K. Protein A potentiates lymphokine-activated killer cell induction in normal and melanoma patient lymphocytes. Immunopharmac. Immunotoxicol. 1992; 14: 79
   Web of Science ®Google Scholar
• Itoh K., Shiiba K., Shimizu Y., Suzuki R., Kumagai K. Generation of activated killer (AK) cells by recombinant interleukin-2 (rIL-2) in collaboration with interferon-y (IFN-y). J. Immunol. 1985; 134: 3124
   Google Scholar
• Ferrini S., Miescher S., Zocchi M. R., Fliedner V. V., Moretta A. Phenotypic and functional characterization of recombinant interleukin-2 (rlL-2)-induced activated killer cells: Analysis at the population and clonal levels. J. Immunol. 1987; 138: 1297
   PubMedGoogle Scholar
• Barlozzari T., Leonhardt J., Wiltrout R. H., Herberman R. D., Reynolds C. W. Direct evidence for the role of LGL in the inhibition of experimental tumor metastases. J. Immunol. 1987; 134: 2783
   Google Scholar
• Mitchell M. S. Combining chemotherapy with biological response modifiers in treatment of cancer. JNCI 1988; 80: 1445
   PubMed Web of Science ®Google Scholar
• Mitchell M. S., Kempf R. A., Hard W., Shau H., Boswell W. D., Lind S., Dean G., Moore J., Bradley E. C. Effectiveness and tolerability of low-dose cyclophosphamide and low dose interleukin-2 in the treatment of disseminated melanoma. J. Clin. Oncol. 1988; 6: 409
   PubMed Web of Science ®Google Scholar
• Pross H. F., Baines M. G., Rubin P., Shragge P., Patterson M. S. Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. the quantitation of natural killer cell activity. J. Clin. Immunol. 1981; 1: 51
   PubMed Web of Science ®Google Scholar
• Mitchell M. S., Kempf R. A., Harel W., Shau H., Boswell W. D., Lind S., Dean G., Moore J., Bradley E. C. Low-dose cyclophosphamide and low-dose interleukin-2 for malignant melanoma. Bull. N. Y. Acad. Med. 1989; 65: 128
   Google Scholar
• Papa M. Z., Yang J. C., Vetto J. T., Shiloni E., Eisenthal A., Rosenberg S. A. Combined effects of chemotherapy and interleukin-2 in the therapy of mice with advanced pulmonary tumors. Cancer Res. 1988; 48: 122
   PubMed Web of Science ®Google Scholar
• Wiltrout R. H., Salup R. R. Adoptive immunotherapy in combination with chemotherapy for cancer treatment. Prog. Exp. Tumor Res. 1988; 32: 128
   Google Scholar
• Yu P. P., Paciucci P. A., Holland J. F. Activity of recombinant human interleukin-2 (IL-2) and doxorubicin in tumor bearing BL/6 mice. Proc. Am. Assoc. Cancer Res. 1986; 27: 317
   Google Scholar
• Ray P. K., Dohadwala M., Bandyopadhyay S. K., Canchanapan P., McLaughlin D. Rescue of rats from large dose cyclophosphamide toxicity using protein A. Cancer Chemother. Pharmacol. 1985; 14: 59
   PubMed Web of Science ®Google Scholar
• Zaidi S. I.A., Singh K. P., Raisuddin S., Saxena A. K., Ray P. K. Protein A induced abrogation of cyclophosphamide toxicity is associated with concomitant protection of immune function of host. Immunopharmac. Immunotoxicol. 1990; 12: 479
   PubMed Web of Science ®Google Scholar
• Dohadwala M., Ray P. K. In vivo protection by protein A of hepatic microsomal mixed oxygenase system of cyclophosphamide treated rats. Cancer Chemother. Pharmacol. 1984; 14: 135
   Web of Science ®Google Scholar
• Ades E. W., Hinson A. Protective effect(s) of rIL-2 modulation I. the effects of chemotherapeutic/cytotoxic agents on human natural killer cells and lymphokine activated killer cells. J. Immunopharmac. 1986; 8: 481
   Google Scholar
• Butler L. D., Browne C. A., Hinson A., Ades E. W. Natural Immunity and Biological Response Modification, C. Chung, R. Herberman. Academic Press, New York 1986
   Google Scholar